Literature DB >> 16825794

The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis.

C Binquet1, C Quantin, G Le Teuff, J F Pagliano, M Abrahamowicz, T Moreau.   

Abstract

The evolution of multiple sclerosis (MS) and the resulting disability are unpredictable. To identify clinical variables that could be potential prognostic factors, we followed a cohort of 288 patients diagnosed as having relapsing-remitting MS between 1990 and 2003. The end point was the first occurrence of a non-reversible EDMUS-GS score >or=3 (moderate disability). The impact of the number of MS attacks during the first 2 years of the disease as well as the first interattack interval were assessed in two Cox models, one using a fixed-in-time covariate, the other using a time-dependent covariate. Older age at onset and a higher number of MS attacks during the first 2 years of MS proved to be predictors of unfavourable prognosis. The first interattack interval had no influence on the evolution of the disability, conversely to the first relapse which had a short-term impact on the prognosis. We confirmed that the age at onset and the number of MS attacks during the first 2 years of MS are predictors of the evolution of the disability and demonstrated the importance of using time-dependent covariates.

Entities:  

Mesh:

Year:  2006        PMID: 16825794     DOI: 10.1159/000094380

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  5 in total

1.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Authors:  Martina Novotna; M Mateo Paz Soldán; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; John H Noseworthy; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

2.  No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Authors:  Madlyne Becker; Clotilde Latarche; Emilie Roman; Marc Debouverie; Catherine Malaplate-Armand; Francis Guillemin
Journal:  BMC Neurol       Date:  2015-05-13       Impact factor: 2.474

Review 3.  Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review.

Authors:  Leoni Rolfes; Steffen Pfeuffer; Tobias Ruck; Nico Melzer; Marc Pawlitzki; Michael Heming; Marcus Brand; Heinz Wiendl; Sven G Meuth
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

4.  Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab.

Authors:  Matthew Craner; Yaser Al Malik; Fawzi A Babtain; Foziah Alshamrani; Mona M Alkhawajah; Nora Alfugham; Rumaiza H Al-Yafeai; Salman Aljarallah; Seraj Makkawi; Shireen Qureshi; Marina Ziehn; Hazem Wahba
Journal:  Neurol Ther       Date:  2022-09-01

5.  Predicting the profile of increasing disability in multiple sclerosis.

Authors:  Valentina Tomassini; Fulvia Fanelli; Luca Prosperini; Raffaella Cerqua; Paola Cavalla; Carlo Pozzilli
Journal:  Mult Scler       Date:  2018-08-02       Impact factor: 6.312

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.